Thursday, 14 December 2006

# **India Morning Meeting Notes**

TODAY'S STORIES

Federal-Mogul Goetze India - Looks ready to deliver

Produced by: ABN AMRO Bank N.V. (India)



Mohan Swamy

mohan.swamy@in.abnamro.com +9122 6715 5304

## **Company news**

# Federal-Mogul Goetze India (FMGI IN; Rs401.70; Buy) – Looks ready to deliver

FMGI looks well positioned to benefit from its trained manpower and facilities with its parent eager to shift 25 plants to low-cost countries within three years. The dieselisation of domestic cars is in its favour, so we stay at Buy and raise our target price to Rs583.

Key forecasts					
	FY04A	FY05A	FY06F	FY07F	FY08F
Revenue (Rsm)	4487.6	4571.4	4045.4	6774.7	8088.6
EBITDA (Rsm)	919.8	698.0	693.8	1425.1	1782.9
Reported net profit (Rsm)	237.0	-487.4	106.6	527.6	767.2
Normalised net profit (Rsm) <sup>1</sup>	353.6	2.35	208.4	627.6	867.2
Normalised EPS (Rs)	14.0	0.09	8.24	24.8	34.3
Dividend per share (Rs)	4.00	0.00	0.00	1.00	1.50
Dividend yield (%)	1.00	0.00	0.00	0.25	0.37
Normalised PE (x)	28.7	4320.5	48.7	16.2	11.7
EV/EBITDA (x)	14.9	20.1	19.9	9.02	6.93
Price/book value (x)	6.41	10.5	9.65	4.07	3.18
ROIC (%)	9.95	4.63	5.70	14.5	16.7

<sup>1.</sup> Post-goodwill amortisation and pre-exceptional items Source: Company data, ABN AMRO forecasts Accounting Standard: Local GAAP

# Back to profits in 2Q, with impressive margins

FMGI returned profits for quarter 2QCY06, as the restructuring-led clean-up of the balance sheet was carried out over the March and June 2006 quarters. FMGI reported an 18.9% EBITDA margin in the September 2006 quarter vs 11.1% in the June 2006 quarter as operations stabilised under parent Federal-Mogul's new systems.

# Ready to gain from parent's eagerness to move to low-cost countries

FMGI's parent has moved quickly to clean up and streamline operations in India over the past two quarters. With its skilled manpower and capability, the company is well positioned to benefit from its parent's plan to shift 25 plants to low-cost countries by 2008, under its 2006 restructuring programme. Given 10 plant closures have already been announced globally, we expect benefits to begin to accrue for FMGI as early as calendar 1Q07, with the company building scale from that point forward.

## We adjust our forecasts for the changed year-end

FMGI has changed its year-end from March to December to get in sync with its parent. We have adjusted our forecasts accordingly and have incorporated the impact of the balance sheet clean-up on financials. We expect the dieselisation of domestic cars in India to promote 18% growth in domestic sales for CY07 and CY08, and we expect exports to grow more than five-fold as a result of the parent's proposed plant shift. We expect PAT to quadruple for CY06-08, leading to EPS of Rs24.8 in CY07F and Rs34.3 in CY08F.

Important disclosures and analyst certifications regarding companies can be found in the Disclosure Appendix.

www.abnamroresearch.com

<sup>\*</sup>Mar yr-ending for 04 & 05, Dec yr-ending from 06F year to Dec, fully diluted

# We maintain our Buy recommendation, with 46% upside potential

An aggressive sales ramp-up as a result of the car dieselisation drive, where FMGI has a monopoly, coupled with significant export opportunities to FM's clients as a result of written-down plants, offers impressive potential profitability growth and ROE improvement. FMGI's stock has had an 80% return in the nine months since the change of parent, but it looks attractively valued at 11.7x CY08F EPS and 8.2x CY08F cash EPS of Rs48.7 cum rights. With a rights issue giving existing investors an opportunity to participate in growth without diluting holdings, we reiterate our Buy rating. We increase our target price from Rs535 to Rs583, which is at 17x CY08F EPS, representing 9.4x EV/EBITDA for CY08F.

## **News headlines**

## **Economics and Politics**

Block deals make 8% of BSE turnover in '06 (Financial Express)

#### Oil and Gas

Shell in talks to buy up to 15% in OVL's Nigerian blocks (Financial Express)

### **Banks**

ICICI hikes loan rates by 50bp (Business Standard)

#### **Pharma**

Morepen files suit against Swiss firm over contract (Business Standard) Glenmark to put US\$2mn in phase-1 trials of pain drug (Business Standard) Ranbaxy plans retail, education foray (Economic Times)

## **Commodities**

CSN has US\$12bn kitty for Corus (Business Standard)

## Auto

Mahindra & Mahindra allots shares on conversion of FCCBs (Business Line)

# IT, Telecom, Media

L&T Infotech acquires US-based GDA Tech (Business Standard)
India adds 6.79m mobile phone users in November (Financial Express)
FLAG Telecom inks deal with Lanka Bell for undersea cable (Business Line)



### **DISCLOSURES APPENDIX**

## Global disclaimer

© Copyright 2006 ABN AMRO Bank N.V. and affiliated companies ("ABN AMRO"). All rights reserved.

This material was prepared by the ABN AMRO affiliate named on the cover or inside cover page. It is provided for informational purposes only and does not constitute an offer to sell or a solicitation to buy any security or other financial instrument. While based on information believed to be reliable, no guarantee is given that it is accurate or complete. While we endeavour to update on a reasonable basis the information and opinions contained herein, there may be regulatory, compliance or other reasons that prevent us from doing so. The opinions, forecasts, assumptions, estimates, derived valuations and target price(s) contained in this material are as of the date indicated and are subject to change at any time without prior notice. The investments referred to may not be suitable for the specific investment objectives, financial situation or individual needs of recipients and should not be relied upon in substitution for the exercise of independent price. Neither ABN AMRO nor other persons shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way from the information contained in this material. This material is for the use of intended recipients only and the contents may not be reproduced, redistributed, or copied in whole or in part for any purpose without ABN AMRO's prior express consent. In any jurisdiction in which distribution to professional and institutional investors.

Australia: Any report referring to equity securities is distributed in Australia by ABN AMRO Equities Australia Ltd (ABN 84 002 768 701, AFS Licence 240530), a participant of the ASX Group. Any report referring to fixed income securities is distributed in Australia by ABN AMRO Bank NV (Australia Branch) (ABN 84 079 478 612, AFS Licence 238266). Australian investors should note that this document was prepared for wholesale investors only.

Canada: The securities mentioned in this material are available only in accordance with applicable securities laws and may not be eligible for sale in all jurisdictions. Persons in Canada requiring further information should contact ABN AMRO Incorporated.

Denmark: ABN AMRO Securities (Nordic) SE is authorised and regulated in Sweden by the Swedish Financial Supervisory Authority. In addition, ABN AMRO Securities (Nordic) SE, Copenhagen Branch is subject to local supervision by Finanstilsynet, the Danish Financial Supervisory Authority. ABN AMRO Securities (Nordic) SE has adopted rules to ensure the integrity and independence of research analysts and the research function, as well as to identify, manage, avoid or make public actual or potential conflicts of interest relating to analysts or ABN AMRO. All analysts located in Denmark follow the recommendations from the Danish Securities Dealers Association.

Finland: ABN AMRO Securities (Nordic) SE is authorised and regulated in Sweden by the Swedish Financial Supervisory Authority. In addition, ABN AMRO Securities (Nordic) SE, Helsinki Branch is subject to local supervision by Rahoitustarkastus, the Financial Supervisory Authority of Finland. ABN AMRO Securities (Nordic) SE has adopted rules to ensure the integrity and independence of research analysts and the research function, as well as to identify, manage, avoid or make public actual or potential conflicts of interest relating to analysts or ABN AMRO.

Hong Kong: This document is being distributed in Hong Kong by, and is attributable to, ABN AMRO Asia Limited which is regulated by the Securities and Futures Commission of Hong Kong.

India: Shares traded on stock exchanges within the Republic of India may only be purchased by different categories of resident Indian investors, Foreign Institutional Investors registered with The Securities and Exchange Board of India ("SEBI") or individuals of Indian national origin resident outside India called Non Resident Indians ("NRIs") and Overseas Corporate Bodies ("OCBs"), predominantly owned by such persons or Persons of Indian Origin (PIO). Any recipient of this document wanting additional information or to effect any transaction in Indian securities or financial instrument mentioned herein must do so by contacting a representative of ABN AMRO Asia Equities (India) Limited.

Italy: Persons in Italy requiring further information should contact ABN AMRO Bank N.V. Milan Branch.

Japan: This report is being distributed in Japan by ABN AMRO Securities Japan Ltd to institutional investors only.

Malaysia: ABN AMRO research, except for economics and FX research, is not for distribution or transmission into Malaysia.

New Zealand: This document is distributed in New Zealand by ABN AMRO NZ Limited an accredited NZX Firm

Russia: The Russian securities market is associated with several substantial risks, legal, economic and political, and high volatility. There is a relatively high measure of legal uncertainty concerning rights, duties and legal remedies in the Russian Federation. Russian laws and regulations governing investments in securities markets may not be sufficiently developed or may be subject to inconsistent or arbitrary interpretation or application. Russian securities are often not issued in physical form and registration of ownership may not be subject to a centralised system. Registration of ownership of certain types of securities may not be subject to standardised procedures and may even be effected on an ad hoc basis. The value of investments in Russian securities may be affected by fluctuations in available currency rates and exchange control regulations.

Singapore: Any report referring to equity securities is distributed in Singapore by ABN AMRO Asia Securities (Singapore) Pte Limited (RCB Regn No. 198703346M) to clients who fall within the description of persons in Regulation 49 of the Securities and Futures (Licensing and Conduct of Business) Regulations and Regulations 34 and 35 of the Financial Advisers Regulations. Any report referring to non-equity securities is distributed in Singapore by ABN AMRO Bank NV (Singapore Branch) Limited to clients who fall within the description of persons in Regulations 34 and 35 of the Financial Advisers Regulations. Investors should note that this material was prepared for accredited investors only. Recipients who do not fall within the description of persons under Regulation 49 of the Securities and Futures (Licensing and Conduct of Business) Regulations or Regulations 34 and 35 of the Financial Advisers Regulations should seek the advice of their independent financial advisor prior to taking any investment decision based on this document or for any necessary explanation of its contents.

Sweden: ABN AMRO Securities (Nordic) SE is authorised and regulated in Sweden by the Swedish Financial Supervisory Authority. ABN AMRO Securities (Nordic) SE has adopted rules to ensure the integrity and independence of research analysts and the research function, as well as to identify, manage, avoid or make public actual or potential conflict of interests relating to analysts or ABN AMRO.

Thailand: Pursuant to an agreement with Asia Plus Securities Public Company Limited (APS), reports on Thai securities published out of Thailand are prepared by APS but distributed outside Thailand by ABN AMRO Bank NV and affiliated companies. Responsibility for the views and accuracy expressed in such documents belongs to APS.

United Kingdom: All research is distributed by ABN AMRO Bank NV, London Branch, which is authorised by De Nederlandsche Bank and by the Financial Services Authority; and regulated by the Financial Services Authority for the conduct of UK business. The investments and services contained herein are not available to private customers in the United Kingdom.

United States: Except for any documents relating to foreign exchange, FX or global FX, distribution of this document in the United States or to US persons is intended to be solely to major institutional investors as defined in Rule 15a-6(a)(2) under the US Securities Act of 1934. All US persons that receive this document by their acceptance thereof represent and agree that they are a major institutional investor and understand the risks involved in executing transactions in securities. Any US recipient of this document wanting additional information or to effect any transaction in any security or financial instrument mentioned herein, must do so by contacting a registered representative of ABN AMRO Incorporated, Park Avenue Plaza, 55 East 52nd Street, New York, N.Y. 10055, US, tel + 1 212 409 1000, fax +1 212 409 5222.

- Material means all research information contained in any form including but not limited to hard copy, electronic form, presentations, e-mail, SMS or WAP.

 $ABN\ AMRO's\ policy\ on\ managing\ research\ conflicts\ of\ interest\ can\ be\ found\ at\ https://www.abnamroresearch.com/Disclosure/Disclosure/AspX?MI=5.$ 

The research analyst or analysts responsible for the content of this research report certify that: (1) the views expressed and attributed to the research analyst or analysts in the research report accurately reflect their personal opinion(s) about the subject securities and issuers and/or other subject matter as appropriate; and, (2) no part of his or her compensation was, is or will be directly or indirectly related to the specific recommendations or views contained in this research report. On a general basis, the efficacy of recommendations is a factor in the performance appraisals of analysts.

For a discussion of the valuation methodologies used to derive our price targets and the risks that could impede their achievement, please refer to our latest published research on those stocks at www.abnamroresearch.com.

Disclosures regarding companies covered by ABN AMRO group can be found on ABN AMRO's research website at www.abnamroresearch.com.

Should you require additional information please contact the relevant ABN AMRO research team or the author(s) of this report.

ABN-AMRO INDIA MORNING MEETING 14 DECEMBER 2006 3